Research Findings from University of Texas MD Anderson Cancer Center Update Understanding of Mantle Cell Lymphoma (The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma).

A recent study conducted at the University of Texas MD Anderson Cancer Center has revealed promising findings regarding the treatment of mantle cell lymphoma (MCL). The study focused on the development of resistance to current therapies, such as inhibitors of Bruton's tyrosine kinase (BTKi) and chimeric antigen receptor T-cell (CAR-T) therapy. Researchers discovered that targeting cyclin-dependent kinase 9 (CDK9) with the CDK9 inhibitor enitociclib showed potential in overcoming therapeutic resistance in MCL models. The study suggests that enitociclib could be a valuable addition to the treatment options for MCL patients. [Extracted from the article]